Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Monday, August 3rd. Get Oruka Therapeutics alerts:View Our Latest Analysis on Oruka TherapeuticsOruka Therapeutics Stock PerformanceShares of NASDAQ ORKA traded down $1.59 during mid-day trading on Tuesday, reaching $103.55. Oruka Therapeutics Company Profile(Get Free Report)Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. Featured StoriesReceive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.